Steve Staben - Associate Director, Senior Scientist, Discovery Chemistry

Steve Staben

Associate Director, Senior Scientist, Discovery Chemistry

Postdoc Mentor
"I’m driven by the impact applied organic chemistry can have on addressing broad therapeutic challenges"
10
Years at Genentech
16
Publications
8
Awards & Honors

I joined the Discovery Chemistry (medicinal chemistry) group at Genentech in 2007 after completing my PhD in organic chemistry at UC Berkeley. My current role includes leading interdisciplinary teams directed toward the common goal of delivering novel therapeutics that can impact patient’s lives.

Postdoctoral Mentor

One of the great things about Genentech is a strong investment in basic scientific research that includes a postdoctoral program. Combine that with great infrastructure, support-teams and resources, and I think we are uniquely positioned to tackle challenging scientific questions. I really enjoy the opportunity to work together with my colleagues to answer basic scientific curiosities that we share.

Featured Publication

Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1H-1,2–4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity

J. Med. Chem. 2013; 56, 4597-4610

Ndubaku CO, Heffron TP, Staben ST, Baumgardner M, Blaquiere N, Bradley E, Bull R, Do S, Dotson J, Dudley D, Edgar KA, Friedman LS, Goldsmith R, Heald RA, Kolesnikov A, Lee L, Lewis C, Nannini M, Nonomiya J, Pang J, Price S, Prior WW, Salphati L, Sideris S, Wallin JJ, Wang L, Wei B, Sampath D, Olivero AG.